From the record

A personalized mRNA cancer vaccine developed by Moderna and Merck reduced the risk of melanoma recurrence or death by 42% in a Phase 3 clinical trial.

Items older than 7 days — their verdicts, sources and coverage history — are part of the Azimuth Daily record and available to signed-in readers.